Next |
home / stock / ovid / ovid message board
Subject | By | Source | When |
---|---|---|---|
The trading last up | Mamameloconto | investorshub | 05/02/2023 1:18:07 PM |
The trading | MfridgeV2 | investorshub | 05/02/2023 3:37:39 AM |
Price trading last up | saj | investorshub | 05/01/2023 4:39:11 PM |
Price now last trade up | Mamameloconto | investorshub | 04/30/2023 3:54:51 PM |
$OVID When is this gonna take off? | Nfixus | investorshub | 04/30/2023 10:53:58 AM |
$OVID The trading last up | Market_scab | investorshub | 04/28/2023 10:07:32 PM |
$OVID great news | FROZENFLAME | investorshub | 04/28/2023 11:03:40 AM |
$OVID MomentumIts gaining | dirtydozen911 | investorshub | 04/28/2023 9:17:32 AM |
$OVID what do you make of this data? | stockguard | investorshub | 04/27/2023 5:50:34 AM |
just the news we needed | Market_scab | investorshub | 04/27/2023 4:25:02 AM |
$OVID here we go bulls news is here | Mamameloconto | investorshub | 04/26/2023 8:43:56 PM |
$OVID just the news we needed | dirtydozen911 | investorshub | 04/26/2023 4:47:17 PM |
Price gaining | ClayTrader | investorshub | 04/24/2023 3:23:38 PM |
just the news we needed | dannyzee84 | investorshub | 04/22/2023 6:14:16 PM |
Good read | FROZENFLAME | investorshub | 04/21/2023 2:12:31 PM |
where is the squeeze? | FROZENFLAME | investorshub | 04/21/2023 8:45:40 AM |
MomentumIts gaining last up | ClayTrader | investorshub | 04/17/2023 11:45:03 PM |
$OVID Looks pretty positive | Munchy | investorshub | 04/14/2023 6:52:20 PM |
short squeeze signal | ClayTrader | investorshub | 04/11/2023 6:06:15 AM |
Looks pretty positive | stoner422 | investorshub | 04/08/2023 11:54:39 PM |
News, Short Squeeze, Breakout and More Instantly...
Ovid Therapeutics Inc. Company Name:
OVID Stock Symbol:
NASDAQ Market:
Ovid Therapeutics Inc. Website:
Neurologists/epileptologists Dr. Imad Najm of the Cleveland Clinic Neurological Institute and the Cleveland Clinic Epilepsy Center, and Dr. Raman Sankar, the Emeritus Chief of Pediatric Neurology at UCLA Health, appointed to Ovid’s Scientific Advisory Board (SAB) Neuroscientists Dr. Ja...
Sustained exposure to OV329 in preclinical models reduced GABA-aminotransferase (GABA-AT) activity, increased steady state GABA levels in the brain, and induced phasic and tonic inhibition OV329 demonstrated anti-convulsant effects in mice, reducing the severity of status epilepticus and pr...
The Phase 1 study for OV888/GV101 capsule met its objective, demonstrating a favorable safety and tolerability profile with no serious adverse events Secondary endpoint results indicate that the target pharmacokinetic profile was achieved at the targeted clinical dose, supporting once daily d...